Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study

被引:2
作者
Ishigo, Tomoyuki [1 ]
Fujii, Satoshi [1 ]
Ibe, Yuta [1 ]
Aigami, Tomohiro [1 ]
Nakano, Keita [1 ]
Fukudo, Masahide [1 ]
Yoshida, Hiroaki [2 ]
Tanaka, Hiroaki [2 ]
Ebihara, Fumiya [3 ]
Maruyama, Takumi [3 ]
Hamada, Yukihiro [3 ]
Suzuki, Ayako [4 ]
Fujihara, Hisato [4 ]
Yamaguchi, Fumihiro [5 ]
Samura, Masaru [6 ,7 ]
Nagumo, Fumio [6 ]
Chiba, Hiroaki [10 ]
Takuma, Akitoshi
Komatsu, Toshiaki [8 ]
Tomizawa, Atsushi [8 ,9 ]
Nishi, Yoshifumi [11 ]
Enoki, Yuki [7 ]
Taguchi, Kazuaki [7 ]
Matsumoto, Kazuaki [7 ]
机构
[1] Sapporo Med Univ Hosp, Dept Pharm, Sapporo, Japan
[2] Kyorin Univ Hosp, Dept Pharm, Mitaka, Japan
[3] Tokyo Womens Med Univ Hosp, Dept Pharm, Tokyo, Japan
[4] Showa Univ, Dept Pharm, Fujigaoka Hosp, Yokohama, Japan
[5] Showa Univ, Dept Resp Med, Fujigaoka Hosp, Yokohama, Japan
[6] Yokohama Gen Hosp, Dept Pharm, Yokohama, Japan
[7] Keio Univ, Fac Pharm, Div Pharmacodynam, Tokyo 1058512, Japan
[8] Kitasato Univ Hosp, Dept Pharm, Sagamihara, Japan
[9] Showa Univ, Dept Pharm, Northern Yokohama Hosp, Yokohama, Japan
[10] Tohoku Kosai Hosp, Dept Pathol, Sendai, Japan
[11] Nihon Univ, Ctr Pharmacist Educ, Sch Pharm, Funabashi, Japan
关键词
Vancomycin; Therapeutic drug monitoring; Decision -tree analysis; Area under the concentration -time curve; AUGMENTED RENAL CLEARANCE; PHARMACOKINETICS; EPIDEMIOLOGY;
D O I
10.1016/j.jiac.2023.11.001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: In therapeutic drug monitoring (TDM) of vancomycin (VCM), the area under the concentration-time curve (AUC) is related to the clinical efficacy and toxicity. Therefore, herein, we examined the factors associated with achieving the target AUC at follow-up and developed a decision flowchart for achieving the target AUC in critically ill patients. Methods: This multicenter retrospective observational study was conducted at eight hospitals. We retrospectively analyzed data from patients who had received VCM in the intensive care unit from January 2020 to December 2022. Decision-tree (DT) analysis was performed using factors with p < 0.1 in univariate analysis as the independent variables. Case data were split up to two times, and four subgroups were included. The primary endpoint was achieving the target AUC at the follow-up TDM (AUC(follow-u)p) and target AUC(follow-up) achievement was defined as an AUC of 400-600 mu g center dot h/mL. The initial AUC values were calculated with the 2-point concentrations (peak and trough) using the Bayesian estimation software Practical AUC-guided TDM (PAT). Results: Among 70 patients (median age [interquartile range], 66 [56, 79] years; 50 % women), the AUC(follow-up) was achieved in 70 % (49/70). Three factors were selected for the decision flow chart: predicted AUC(follow-up) of 400-600 mu g center dot h/mL, dosing at 12-h intervals, and CCr of 130 mL/min/1.73 m(2) or higher; the accuracy was adequate (92 %, R-2 0.52). Conclusion: We successfully identified the factors associated with achieving the target AUC of VCM at follow-up TDM and developed a simple-to-use DT model. However, the validity of the findings needs to be evaluated.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 33 条
  • [1] Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance
    Chu, Yang
    Luo, Yifan
    Ji, Shuangmin
    Jiang, Mingyan
    Zhou, Baosen
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2020, 13 (01) : 68 - 74
  • [2] Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy
    Claus, Barbara O. M.
    Hoste, Eric A.
    Colpaert, Kirsten
    Robays, Hugo
    Decruyenaere, Johan
    De Waele, Jan J.
    [J]. JOURNAL OF CRITICAL CARE, 2013, 28 (05) : 695 - 700
  • [3] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [4] THE EPIDEMIOLOGY OF INTRAVENOUS VANCOMYCIN USAGE IN A UNIVERSITY HOSPITAL - A 10-YEAR STUDY
    ENA, J
    DICK, RW
    JONES, RN
    WENZEL, RP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (05): : 598 - 602
  • [5] Finch NA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01293-17, 10.1128/aac.01293-17]
  • [6] Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients
    Hashimoto, Naoto
    Kimura, Toshimi
    Hamada, Yukihiro
    Niwa, Takashi
    Hanai, Yuki
    Chuma, Masayuki
    Fujii, Satoshi
    Matsumoto, Kazuaki
    Shigemi, Akari
    Kawamura, Hideki
    Takahashi, Yoshiko
    Takesue, Yoshio
    [J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 27 : 12 - 19
  • [7] Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis
    Hefny, Fatma
    Stuart, Anna
    Kung, Janice Y.
    Mahmoud, Sherif Hanafy
    [J]. PHARMACEUTICS, 2022, 14 (02)
  • [8] Simulation of Vancomycin Exposure Using Trough and Peak Levels Achieves the Target Area under the Steady-State Concentration-Time Curve in ICU Patients
    Ibe, Yuta
    Ishigo, Tomoyuki
    Fujii, Satoshi
    Takahashi, Satoshi
    Fukudo, Masahide
    Sato, Hideki
    [J]. ANTIBIOTICS-BASEL, 2023, 12 (07):
  • [9] Construction of a risk prediction model of vancomycin-associated nephrotoxicity to be used at the time of initial therapeutic drug monitoring: A data mining analysis using a decision tree model
    Imai, Shungo
    Yamada, Takehiro
    Kasashi, Kumiko
    Niinuma, Yusuke
    Kobayashi, Masaki
    Iseki, Ken
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2019, 25 (01) : 163 - 170
  • [10] Effect of renal clearance on vancomycin area under the concentration-time curve deviations in critically ill patients
    Ishigo, Tomoyuki
    Ibe, Yuta
    Fujii, Satoshi
    Kazuma, Satoshi
    Aigami, Tomohiro
    Kashiwagi, Yuri
    Takada, Ryo
    Takahashi, Satoshi
    Fukudo, Masahide
    Toda, Takaki
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2023, 29 (08) : 769 - 777